Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Sales (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Return on Sales readings, the most recent being 0.0% for Q1 2026.

  • On a quarterly basis, Return on Sales changed 0.0% to 0.0% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.0%, a 0.0% change, with the full-year FY2025 number at 0.0%, changed 0.0% from a year prior.
  • Return on Sales hit 0.0% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 0.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.02% in Q3 2022 to a low of 0.01% in Q4 2023.
  • Median Return on Sales over the past 5 years was 0.0% (2024), compared with a mean of 0.0%.
  • Biggest five-year swings in Return on Sales: rose 5bps in 2022 and later decreased -2bps in 2023.
  • Kiniksa Pharmaceuticals International's Return on Sales stood at 0.01% in 2022, then plummeted by -263bps to 0.01% in 2023, then skyrocketed by 99bps to 0.0% in 2024, then skyrocketed by 809bps to 0.0% in 2025, then soared by 50bps to 0.0% in 2026.
  • The last three reported values for Return on Sales were 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025) per Business Quant data.